Therapeutic Potential of (47)Sc in Comparison to (177)Lu and (90)Y: Preclinical Investigations

Targeted radionuclide therapy with (177)Lu- and (90)Y-labeled radioconjugates is a clinically-established treatment modality for metastasized cancer. (47)Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy β(−)-particles. In this study, (47)Sc was inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Siwowska, Klaudia, Guzik, Patrycja, Domnanich, Katharina A., Monné Rodríguez, Josep M., Bernhardt, Peter, Ponsard, Bernard, Hasler, Roger, Borgna, Francesca, Schibli, Roger, Köster, Ulli, van der Meulen, Nicholas P., Müller, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723926/
https://www.ncbi.nlm.nih.gov/pubmed/31434360
http://dx.doi.org/10.3390/pharmaceutics11080424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723926/
https://www.ncbi.nlm.nih.gov/pubmed/31434360
http://dx.doi.org/10.3390/pharmaceutics11080424

Ejemplares similares